When evaluating copy number alterations (CNAs), of the 223 patients for which this information was available, we found that 3% of NSCLC patients showed deep deletion of SPINT1, and 53% had shallow deletion (Fig 1A). This evidence concerns the gene SPINT1 and non-small cell lung carcinoma.